Gisev Natasa, Nielsen Suzanne, Cama Elena, Larance Briony, Bruno Raimondo, Degenhardt Louisa
National Drug and Alcohol Research Centre, UNSW, Australia, Sydney, NSW, 2052, Australia.
School of Medicine, University of Tasmania, Hobart, Australia.
Eur J Clin Pharmacol. 2016 Apr;72(4):469-94. doi: 10.1007/s00228-015-1995-8. Epub 2015 Dec 22.
The extent and factors associated with codeine use in the community remain poorly understood despite the widespread global use of codeine. The aim of this study was to examine the use of prescription and over-the-counter (OTC) codeine in Australia and identify the geographic and socio-demographic characteristics associated with prescription and OTC codeine use.
National sales data for prescription and OTC codeine (supplied by IMS Health) were used to estimate codeine utilisation (in pack sales and milligrammes) in Australia during 2013, mapped to Australian Bureau of Statistics (ABS) Statistical Local Areas (SLAs) and Remoteness Areas. Socio-demographic characteristics and total population estimates of SLAs were obtained from the ABS. SLA-level data on sex, age distribution, income, occupations involving physical labour and number of pharmacies were included in linear regression analyses to examine their association with total, prescription and OTC codeine use.
In total, 27,780,234 packs of codeine were sold in Australia during 2013, equating to 12,376 kg. OTC codeine preparations accounted for 15,490,207 packs (55.8 %) or 4967.30 kg (40.1 %). Nationally, an estimated 1.24 packs (or 554.10 mg) of codeine were sold per person; utilisation was higher in more remote areas. SLAs with a higher percentage of low-income earning households had the highest rates of prescription codeine use (β 0.16, p < 0.001), whereas SLAs with a higher percentage of males had the highest rates of OTC codeine use (β 0.22, p < 0.001).
Codeine use is common in Australia, with clear distinctions in the geographic and socio-demographic characteristics associated with prescription and OTC codeine use.
尽管可待因在全球广泛使用,但社区中可待因的使用范围及相关因素仍知之甚少。本研究的目的是调查澳大利亚处方和非处方(OTC)可待因的使用情况,并确定与处方和OTC可待因使用相关的地理和社会人口特征。
使用IMS Health提供的处方和OTC可待因的全国销售数据来估计2013年澳大利亚可待因的使用量(以包装销售量和毫克计),并映射到澳大利亚统计局(ABS)的统计局部地区(SLA)和偏远地区。SLA的社会人口特征和总人口估计数来自ABS。将SLA层面的性别、年龄分布、收入、体力劳动职业和药店数量数据纳入线性回归分析,以研究它们与可待因总使用量、处方使用量和OTC使用量的关联。
2013年澳大利亚共售出27,780,234包可待因,相当于12,376千克。OTC可待因制剂占15,490,207包(55.8%)或4967.30千克(40.1%)。在全国范围内,人均估计售出1.24包(或554.10毫克)可待因;偏远地区的使用率更高。低收入家庭比例较高的SLA处方可待因使用率最高(β 0.16,p < 0.001),而男性比例较高的SLA的OTC可待因使用率最高(β 0.22,p < 0.001)。
可待因在澳大利亚的使用很普遍,与处方和OTC可待因使用相关的地理和社会人口特征存在明显差异。